Our Medicines
BUPREDERMAL® PATCH
transdermal buprenorphine matrix patch
MS MONO® CAPSULES
modified release morphine sulfate
NORSPAN® PATCH
transdermal buprenorphine matrix patch
ORDINE® ORAL SOLUTION
immediate release morphine hydrochloride
OXYCONTIN® TABLETS
modified release oxycodone hydrochloride
OXYNORM® CAPSULES AND LIQUID
immediate release oxycodone hydrochloride
OXYNORM® INJECTION
immediate release oxycodone hydrochloride
SEVREDOL® TABLETS
immediate release morphine sulfate
TARGIN® TABLETS
modified release oxycodone and modified release naloxone hydrochloride dihydrate
MS CONTIN® TABLETS
modified release morphine sulfate
DILAUDID® TABLETS
immediate release hydromorphone hydrochloride
DILAUDID® & DILAUDID®HP INJECTIONS
hydromorphone hydrochloride
Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is required at initiation, maintenance and tapering of opioid therapy.
Mundipharma is not promoting the use of strong opioids (excluding the 7-day buprenorphine transdermal patch) in chronic non-cancer pain.
® MS MONO, NORSPAN, OXYCONTIN, OXYNORM, SEVREDOL, MS CONTIN, DILAUDID and TARGIN are registered trade marks of Mundipharma.
® ORDINE is a registered trade mark of Pfizer (Perth) Pty Ltd and is used under licence.
Reporting adverse events
Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/
Adverse events can also be reported to Mundipharma at drugsafety@mundipharma.com.au